UBRELVY is available in both 50 mg and 100 mg tablets1

  • Taken orally, with or without food1
  • A second dose can be taken at least 2 hours after the initial dose (if needed)1

    UBRELVY demonstrated second-dose efficacy—55% of patients achieved pain freedom at 2 hours with an optional second dose after first dose pain relief2

  • The maximum daily dose is 200 mg1
  • UBRELVY can be used to treat up to 8 migraines in a 30-day period1

Tablets are not actual size.

Dosing considerations:

  • UBRELVY should not be used concomitantly with strong CYP3A4 inhibitors, such as ketoconazole, itraconazole, or clarithromycin, as they may cause an increase in UBRELVY exposure1
  • Strong CYP3A4 inducers should be avoided as concomitant use will result in reduction of ubrogepant exposure1
  • Patients on moderate or weak CYP3A4 inhibitors or inducers or BCRP and/or P-gp only inhibitors will require dose modifications. See section 2.2 of Prescribing Information
  • Avoid use in patients with end-stage renal disease1
  • Dose adjustment is recommended with concomitant use of UBRELVY and moderate CYP3A4 inhibitors including cyclosporine, ciprofloxacin, fluconazole, fluvoxamine, and grapefruit juice1
  • Severe hepatic or severe renal impairment: Recommended dose is 50 mg; if needed, a second 50 mg dose may be taken at least 2 hours after the initial dose1
  • In clinical trials, patients were able to use concomitant preventive medications including topiramate, onabotulinumtoxinA, propranolol, and amitriptyline3
  • Low rates of rescue medication use were observed in the clinical trial program4*

*Rescue medication was the patient’s usual acute treatment for migraine.

References

1. UBRELVY [package insert]. Madison, NJ: Allergan USA, Inc.; 2019. 2. Ailani J, Blumenfeld AM, Klein B, et al. An optional second dose of ubrogepant is effective in achieving 2-hour pain freedom in the acute treatment of migraine. Poster presented at: 61st Annual Scientific Meeting of the American Headache Society; July 11-14, 2019; Philadelphia, PA. Poster #P112. 3. Data on file. Allergan. 4. Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230-2241.